Lilly Targets Black-Market Retatrutide Sellers
LLY
Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide
The company filed six lawsuits against U.S. businesses it accuses of selling unapproved versions of the drug while it remains in clinical development
Retatrutide is still in Phase 3 trials for obesity, type 2 diabetes and related conditions and has not been approved for human use
Lilly said it has already referred more than 200 individuals and businesses to regulators, law enforcement and professional licensing boards
The crackdown comes as demand for GLP-1 treatments continues to fuel a large online market for compounded and unauthorized weight-loss products
U.S. customs data cited by Reuters also showed a sharp rise in seizures of illicit GLP-1 shipments this year
For investors, the lawsuits highlight how much commercial interest has built around retatrutide before it has even reached the market
The next major catalyst remains whether late-stage trial results can support regulatory approval and turn that demand into legitimate sales
GuruFocusStrategy, business, and productsUS stocks
Read more from GuruFocus
